Graeme Hodgson, Vice President Oncology
Professional Overview
Graeme Hodgson is an accomplished pharmaceutical executive with extensive expertise in translational biology, biomarker development, and oncology research. As the Vice President of Oncology at Omega Therapeutics and a Translational Biology and Biomarker Consultant at JGH Consulting LLC, he leverages his deep scientific knowledge and industry experience to drive innovative drug development and translation of research findings into clinical applications.
Experience Summary
Current Role
As the Vice President of Oncology at Omega Therapeutics, Graeme is responsible for leading the company's oncology-focused research and development initiatives. He oversees the translation of preclinical findings into clinical-stage programs, collaborating closely with cross-functional teams to accelerate the development of novel cancer therapies. Graeme's expertise in translational medicine and biomarker identification has been instrumental in advancing Omega's pipeline and ensuring the efficient progression of oncology projects.
In his concurrent role as a Translational Biology and Biomarker Consultant at JGH Consulting LLC, Graeme provides strategic advisory services to biotechnology and pharmaceutical companies. He leverages his extensive industry knowledge to help clients optimize their research and development strategies, identify relevant biomarkers, and enhance the likelihood of successful clinical outcomes.
Career Progression
Prior to his current roles, Graeme held progressive leadership positions in translational medicine and biomarker development at Syros Pharmaceuticals and ARIAD Pharmaceuticals, Inc. As the Vice President of Translational Medicine at Syros Pharmaceuticals, he was instrumental in establishing the company's translational biology and biomarker capabilities, guiding the advancement of multiple oncology programs from preclinical to clinical stages. Earlier in his career, Graeme served as a Senior Principal Scientist at Pfizer, where he contributed to the development of several oncology and cardiovascular drug candidates.
Academic Background
Graeme holds a Ph.D. in Molecular Biology from the University of California, San Francisco, where he conducted groundbreaking postdoctoral research focused on cancer biology and signal transduction pathways.
Areas of Expertise
- Translational biology and biomarker development
- Oncology drug discovery and development
- Preclinical to clinical translation
- Immunotherapy and targeted therapy strategies
- Cross-functional collaboration and team leadership
- Strategic advisory and consulting services
Professional Impact
Graeme's work has led to the successful advancement of several oncology programs, with his contributions to biomarker identification and validation helping to enhance the clinical success of novel cancer therapies. He has authored numerous peer-reviewed publications and presented his research at prominent scientific conferences, further solidifying his reputation as a thought leader in the field of translational oncology.
Conclusion
With his extensive experience, deep scientific expertise, and proven track record of driving innovation, Graeme Hodgson is well-positioned to continue making significant contributions to the development of transformative oncology treatments. His versatile skillset and strategic vision make him a valuable asset to both Omega Therapeutics and his consulting clients as they navigate the complexities of the ever-evolving pharmaceutical landscape.
